Hematologic Oncology | Specialty

The hematologic oncology condition center is a comprehensive resource for clinical news and expert insights on hematologic oncology. Read more at OncLive.

The OncFive: Top Oncology Articles for the Week of 4/27

May 3rd 2025

The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission, and more.

FDA Grants Fast Track Designation to BI-1808 in Select Cutaneous T-Cell Lymphoma

May 3rd 2025

BI-1808 has received FDA fast track designation for the treatment of patients with select cutaneous T-cell lymphoma subtypes.

sBLA Submission Planned for Epcoritamab/Rituximab/Lenalidomide in R/R FL

May 2nd 2025

An sBLA seeking the approval of epcoritamab plus rituximab and lenalidomide for relapsed/refractory FL is planned to be submitted to the FDA.

ICT01 Plus Azacitidine and Venetoclax Shows Early Evidence of Antitumor Activity in AML

April 29th 2025

A low dose of ICT01 added to combination therapy with azacitidine and venetoclax proved active and safe as frontline therapy in patients with AML.

Addition of Relatlimab/Nivolumab to Azacitidine/Venetoclax Shows Safety, Early Efficacy in Adverse-Risk Frontline AML

April 29th 2025

Although the combination of azacitidine alone plus relatlimab/nivolumab was deemed safe, it had limited efficacy in patients with relapsed/refractory AML.

Five Under 5: Top Oncology Videos for the Week of 4/20

April 27th 2025

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

CHMP Recommends Brentuximab Vedotin Plus ECADD for Newly Diagnosed Stage IIB/III/IV Hodgkin Lymphoma

April 25th 2025

The EMA’s CHMP has recommended the approval of brentuximab vedotin plus ECADD for newly diagnosed, stage IIB/III/IV Hodgkin lymphoma.

Inati-Cel Induces High CR and MRD Negativity Rates in CD19+ R/R B-ALL

April 23rd 2025

Inati-cel generated complete remissions and MRD negativity in CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Mutational Sequencing Evolutions Drive Precision Medicine Approaches for AML

April 22nd 2025

Eunice Wang, MD, provides an overview of currently available AML treatments and highlights the importance of mutational sequencing strategies.

Dasatinib Plus CAR T-Cell Therapy Shows Efficacy in Ph+ Acute Lymphoblastic Leukemia

April 17th 2025

Dasatinib plus CAR T cells led to high CMR and LFS rates with a good safety profile in Ph-positive acute lymphoblastic leukemia.

Glofitamab Plus Chemo Wins European Approval for R/R DLBCL

April 14th 2025

The EC approved glofitamab with gemcitabine/oxaliplatin for patients with relapsed or refractory diffuse large B-cell lymphoma, ineligible for ASCT.

PROs, Gene Expression Vary Among Patients With AML Undergoing Induction Chemo

April 11th 2025

PROs and gene expression in peripheral blood varied in patients with acute myeloid leukemia receiving induction chemotherapy.

Multidisciplinary BiTE-Associated AE Education Increases the Safety of Outpatient Administration

April 10th 2025

Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.

Dr Andorsky on Molecular Responses With Second-Line Asciminib in CP-CML

April 10th 2025

David J. Andorsky, MD, discusses molecular responses achieved with asciminib dose escalation in patients with CP-CML who had received 1 prior TKI.

Dr Ahmed on the Rationale for Evaluating NTKR-255 After CAR T-Cell Therapy in R/R LBCL

April 10th 2025

Sairah Ahmed, MD, explains the rationale for evaluating NTKR-255 after CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

Investigational Microbiotherapy MaaT033 Is Safe in Allo-HSCT Recipients

April 9th 2025

An independent DSMB found MaaT033 to have a favorable safety profile in patients with hematologic malignancies undergoing allo-HSCT in the PHOEBUS trial.

Tambiciclib Generates Potential OS Benefit in R/R AML

April 8th 2025

Tambiciclib generated a median overall survival of 8.8 months in patients with relapsed/refractory acute myeloid leukemia.

FDA Approval Is Sought for Ziftomenib in NMP1-Mutant R/R AML

April 8th 2025

The FDA has received an NDA for ziftomenib in relapsed/refractory NMP1-mutant acute myeloid leukemia.

Five Under 5: Top Oncology Videos for the Week of 3/30

April 6th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

The OncFive: Top Oncology Articles for the Week of 3/30

April 5th 2025

Orca-T boosts cGVHD-free survival in hematologic malignancies, cilta-cel continues to impress in CARTITUDE-4, and more.